Immunotherapy is different from other prostate cancer treatments. It can activate your own immune system to seek out and attack prostate cancer.
Men with advanced prostate cancer have a variety of treatment options. Your treatment choice depends on multiple factors, including the stage of your cancer and your overall health. Some common treatment options include:
Blocks the production or action of male hormones, such as testosterone, which prostate cancer needs to grow
Activates the immune system to seek out and attack prostate cancer
Is a class of drugs used to stop prostate cancer cells from growing
Are a class of drugs that contain a radioactive element, such as radium Ra 223 dichloride (Xofigo®) for men with bone pain from prostate cancer
Lupron Depot is a registered trademark of AbbVie Inc. Eligard is a registered trademark of Tolmar Pharmaceueticals. Zoladex and Casodex are registered trademarks of AstraZeneca. Firmagon is a registered trademark of Ferring Pharmaceuticals. Eulexin is a registered trademark of Schering-Plough. Nizoral and Zytiga are registered trademarks of Janssen Pharmaceuticals. Xtandi is a registered trademark of Astellas Pharma Inc. Taxotere is a registered trademark of Aventis Pharmaceuticals. Jevtana is a registered trademark of Sanofi Genzyme. Novantrone is a registered trademark of EMD Serono, Inc. Xofigo is a registered trademark of Bayer.
PROVENGE, the first immunotherapy for prostate cancer, prolonged life for men with both low and high prostate-specific antigen (PSA) levels. There may be greater survival benefits when men with advanced prostate cancer start PROVENGE while PSA levels are lower.b
aIndividual results may vary.
bAnalysis was exploratory and individual results may vary.
cPSA less than or equal to 22.1 ng/mL.
There are potential risks associated with PROVENGE:
The most common side effects of PROVENGE prostate cancer treatment include:
PROVENGE infusion can cause serious reactions. Tell your doctor right away if:
These are not all the possible side effects of PROVENGE treatment. For more information, talk with your doctor. Please see Important Safety Information.
PSA is a normal protein made by the prostate. In healthy men, some PSA is found in the blood. Measuring PSA levels in the blood is used to look for changes in prostate cancer (ie, disease progression). Once prostate cancer has progressed to advanced disease, PSA may play a smaller role. PSA level in the blood is not a specific marker of treatment success. In the PROVENGE clinical trials, the main goal was not to lower PSA levels—it was to extend life.
PROVENGE may be considered first for some men with advanced prostate cancer (mCRPC).
Your immune system is your body’s natural defense. PROVENGE is designed to work with your immune system to seek out and attack your prostate cancer cells. PROVENGE is made from your own cells to treat your advanced prostate cancer. By activating immune cells already in your body, PROVENGE personalizes the fight against your advanced prostate cancer.
PROVENGE is clinically proven to help extend life in certain men with advanced prostate cancer (mCRPC) who do not need prescription pain medication for cancer-related pain. Learn more about the PROVENGE experience.
The first and only personalized immunotherapy for mCRPC.
Prostate cancer is the second most common cancer among men in America. There are many ways to connect with the large community of men undergoing a similar journey to yours. Start the PROVENGE conversation by using the doctor locator to find a treatment center near you and explore available resources.
PROVENGE® (sipuleucel-T) is a prescription medicine that is used to treat certain patients with advanced prostate cancer. PROVENGE is made from your own immune cells.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information.
Access this brochure to learn about PROVENGE and how it may help certain men with advanced prostate cancer (mCRPC) live longer.